In adults with cystic fibrosis, pancreatic status — that is, being pancreatic sufficient vs being pancreatic insufficient — has been shown to have a pronounced effect on the average rate of decline in lung function.
The FDA has granted Orphan Drug designation to pravibismane suspension for inhalation (BisEDT antimicrobial suspension; Microbion) for the management of pulmonary infections in patients with cystic fibrosis.
Tobacco smoke exposure inhibited the therapeutic benefit of the cystic fibrosis transmembrane conductance regulator modulators in pediatric patients.
Patients with cystic fibrosis who were treated for 1 year with a combination of lumacaftor and ivacaftor saw improvements in glucose tolerance abnormalities
The FDA has granted Fast Track designation to MRT5005, an inhaled messenger RNA (mRNA) therapeutic being investigated for the treatment of cystic fibrosis.
A heterogeneous liver pattern could indicate a higher risk for advanced cystic fibrosis liver disease.
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
Continuous glucose monitoring may provide a better understanding of the early stages of diabetes progression in youth with cystic fibrosis.
A multidisciplinary team discussed exploring the management options for nontuberculous mycobacterial infection in patients with cystic fibrosis.
Significant differences have been observed from bronchoalveolar lavage surveillance conducted among preschool children with cystic fibrosis, according to their country of residence.
